Literature DB >> 19501211

Efficacy and safety of a low-dose combined oral contraceptive containing drospirenone 3 mg and ethinylestradiol 20 mcg in a 24/4-day regimen.

László Hernádi1, Joachim Marr, Dietmar Trummer, Vincenzo De Leo, Felice Petraglia.   

Abstract

OBJECTIVE: The study was conducted to assess the efficacy of a low-dose combined oral contraceptive (COC) containing drospirenone (drsp) 3 mg/ethinylestradiol (EE) 20 mcg administered for 24 days of active treatment followed by a 4-day hormone-free interval (24/4 regimen). STUDY
DESIGN: In this open-label uncontrolled study conducted in 50 European centers, healthy females aged 18-35 years with a body mass index of less than 30 kg/m(2) received drsp 3 mg/EE 20 mcg 24/4 over 13 cycles. The primary efficacy variable was the number of unintended pregnancies.
RESULTS: Five pregnancies occurred among 1101 women over 13,248 treatment cycles, resulting in a Pearl Index (PI) of 0.49 with an upper two-sided 95% CI limit of 1.14. Of these pregnancies, three were attributed to noncompliance with tablet use resulting in an adjusted PI for 'perfect use' of 0.22 (upper limit of two-sided 95% CI: 0.80) based on 11,755 cycles.
CONCLUSION: Drospirenone 3 mg/EE 20 mcg 24/4 is a highly effective COC in nonobese women.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19501211     DOI: 10.1016/j.contraception.2009.01.016

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  5 in total

Review 1.  Contraceptive failure in the United States.

Authors:  James Trussell
Journal:  Contraception       Date:  2011-03-12       Impact factor: 3.375

2.  Contraceptive efficacy and tolerability of ethinylestradiol 20 μg/drospirenone 3 mg in a flexible extended regimen: an open-label, multicentre, randomised, controlled study.

Authors:  Christine Klipping; Ingrid Duijkers; Michel P Fortier; Joachim Marr; Dietmar Trummer; Jörg Elliesen
Journal:  J Fam Plann Reprod Health Care       Date:  2012-04

3.  Adherence with ethinylestradiol 20 μg/drospirenone 3 mg in a flexible extended regimen supported by the use of a digital tablet dispenser with or without acoustic alarm: an open-label, randomized, multicenter study.

Authors:  Inka Wiegratz; Jörg Elliesen; Anna Maria Paoletti; Anja Walzer; Bodo Kirsch
Journal:  Int J Womens Health       Date:  2015-01-05

4.  Efficacy and safety of an oral contraceptive containing ethinylestradiol 20 µg/drospirenone 3 mg (24/4 regimen) in three indications in the People's Republic of China: a comparison with international studies.

Authors:  Joachim Marr; Zirong Huang; Baoxi Wang; Hongyan Zhang; Katrin Roth
Journal:  Open Access J Contracept       Date:  2015-07-10

5.  Needs and preferences of women users of oral contraceptives in selected countries in Central and Eastern Europe.

Authors:  Tomas Fait; Dmitry Buryak; Monica-Mihaela Cirstoiu; Eva Luczai; Rafal Janczura
Journal:  Drugs Context       Date:  2018-02-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.